Full Text View
Tabular View
No Study Results Posted
Related Studies
Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
This study has been completed.
Study NCT00190788   Information provided by Eli Lilly and Company
First Received: September 12, 2005   Last Updated: October 10, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sepsis
Hypotension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Drotrecogin Alfa (Activated)
placebo
Additional drug interventions recognized in this trial
Drotrecogin alfa activated
Protein C
More general drug interventions related to this trial
Anti-Infective Agents
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services